• If you are wondering whether ArriVent BioPharma's current share price lines up with its underlying worth, you are exactly the audience this valuation focused review is written for.
• The stock last closed at US$25.25, with reported returns of 8.7% over 7 days, 11.6% over 30 days, 21.4% year to date, and 15.8% over the past year.
• Recent price moves sit against a backdrop of ArriVent BioPharma working to bring its pipeline to market and building out its position in the pharmaceuticals and biotech space. These developments are front of mind for investors who are weighing how much of that potential is already reflected in the share price.
• On our valuation checklist, ArriVent BioPharma scores 4 out of 6 for being undervalued, giving it a valuation score of 4. Next, we will walk through the usual valuation approaches before finishing with a more complete way to think about what that score really means.

Approach 1: ArriVent BioPharma Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of the cash a company may generate in the future and discounts those amounts back to today to arrive at an estimate of what the business could be worth now.

For ArriVent BioPharma, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest reported free cash flow is a loss of $146.082 million. Analysts have provided estimates out to 2030, where free cash flow is projected at $161.975 million, with later years extrapolated by Simply Wall St rather than based on explicit analyst forecasts.

After discounting all these projected cash flows back to today, the model arrives at an estimated intrinsic value of about $327.51 per share. Compared with the recent share price of US$25.25, this implies the stock is 92.3% undervalued according to this DCF model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests ArriVent BioPharma is undervalued by 92.3%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

Approach 2: ArriVent BioPharma Price vs Book

For companies that are not currently generating positive earnings or sales, the price to book, or P/B, ratio is often a useful way to think about value because it compares what the market is paying to the accounting value of the net assets on the balance sheet.

In broad terms, a higher “normal” P/B can reflect expectations of stronger future growth or lower perceived risk, while a lower P/B can suggest more muted expectations or higher risk. What counts as fair can also differ across sectors, which is why context matters.

ArriVent BioPharma currently trades on a P/B of 3.42x. The broader Biotechs industry average is 2.61x, while the peer group used here sits at about 3.47x. Simply Wall St’s Fair Ratio concept goes a step further. It estimates the P/B you might expect for this specific company after considering factors such as earnings growth, industry, profit margin, market cap and key risks.

Because the Fair Ratio is tailored to ArriVent BioPharma, it can be more informative than looking only at raw industry or peer averages. However, in this case a proprietary Fair Ratio is not available, so we cannot draw a firm conclusion on whether 3.42x points to the shares being overvalued or undervalued relative to that framework.

Result: ABOUT RIGHT

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your ArriVent BioPharma Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple tool on Simply Wall St’s Community page that lets you spell out the story you see for a company, link that story to a forecast for revenue, earnings and margins, and then connect that forecast to your own fair value estimate.

Instead of only looking at static ratios, a Narrative helps you compare your fair value to the current share price so you can decide if ArriVent BioPharma looks attractively priced, fully valued or expensive based on your assumptions. The platform then automatically refreshes that view when new information such as news or earnings is added.

For ArriVent BioPharma, one investor might build a Narrative that supports a fair value close to the DCF estimate of about US$327.51 per share, while another could use more conservative assumptions and land on a much lower fair value. This shows how the same stock can look very different once you make your own story and numbers explicit.

Do you think there's more to the story for ArriVent BioPharma? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.